Related Experiment Video
Updated: Feb 20, 2026
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.4K
Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens
Jinjing Xu1,2, Kang Tian1, Haixu Zhang1
1a Cancer Institute , Xuzhou Medical University , Xuzhou , Jiangsu , China.
Expert Review of Anticancer Therapy
|October 20, 2017
Summary
Chimeric antigen receptor (CAR-T) therapy shows promise for solid tumors. Enhancing clinical regimens through targeted delivery and combination therapies is key to improving CAR-T treatment efficacy.
Area of Science:
- Immunology
- Oncology
- Cell Therapy
Background:
- Chimeric antigen receptor (CAR-T) therapy has revolutionized hematological cancer treatment.
- Significant challenges remain in translating CAR-T success to solid tumors.
Purpose of the Study:
- To review recent clinical trials and identify strategies to improve CAR-T efficacy in solid tumors.
- To discuss factors limiting CAR-T effectiveness and future directions for solid tumor treatment.
Main Methods:
- Review of recent clinical trials involving CAR-T therapy for solid tumors.
- Analysis of current limitations and proposed improvements in CAR-T clinical regimens.
Main Results:
- CAR-T therapy faces challenges in solid tumors, including delivery and tumor microenvironment interactions.
- Promising results necessitate advancements in clinical strategies for broader application.
Conclusions:
- Improving CAR-T efficacy in solid tumors requires enhanced clinical regimens.
- Strategies include local delivery, combination therapies (chemotherapy, immune checkpoint inhibitors), dual-antigen targeting, and post-resection application for recurrence prevention.
